Use of Direct-acting Antiviral Therapy to Prevent Spread of HCV Infection for Patients Receiving a HCV Positive Kidney Transplant as a HCV Negative Recipient
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Oct 2017 Planned End Date changed from 31 Jan 2020 to 31 Jan 2021.
- 04 Oct 2017 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
- 04 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Feb 2018.